Literature DB >> 24636430

Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).

Helio S Sader1, David J Farrell2, Robert K Flamm2, Ronald N Jones2.   

Abstract

We report the results of 8 years (2005-2012) of the Daptomycin Surveillance Programme Worldwide. Consecutive non-duplicate bacterial isolates (prevalence design) were collected from patients with documented infections in 410 medical centres and were susceptibility tested by reference broth microdilution methods. A total of 164457 Gram-positive isolates were evaluated, including 97542 Staphylococcus aureus, 21413 coagulase-negative staphylococci (CoNS), 29619 enterococci and 15883 β-haemolytic streptococci. The prevalence of daptomycin-non-susceptible isolates was extremely low for all species in all geographic regions. Overall, the highest occurrence of non-susceptible isolates was observed among CoNS (0.19%), followed by Enterococcus faecium (0.18%), S. aureus (0.05%), Enterococcus faecalis (0.02%) and β-haemolytic streptococci (0.00%). Moreover, no trend towards increased daptomycin resistance (non-susceptibility) was observed for any species in any geographic region during the study interval. Against S. aureus, the daptomycin MIC(50/90) was 0.25/0.5 mg/L in all geographic regions (99.95% susceptible overall). Only 53 daptomycin-non-susceptible S. aureus isolates were observed and the vast majority (49; 92.5%) had a daptomycin MIC value only 1 log(2) dilution above the published susceptible breakpoint. Daptomycin was also active against CoNS (MIC(50/90), 0.25/0.5 mg/L; 99.81% susceptible), E. faecalis (MIC(50/90), 1/2 mg/L; 99.98% susceptible), E. faecium (MIC(50/90), 2/4 mg/L; 99.82% susceptible) including vancomycin-non-susceptible isolates (4521 isolates; MIC(50/90), 2/2 mg/L; 99.76% susceptible), and β-haemolytic streptococci (MIC(50/90), ≤0.06/0.25 mg/L; 100.0% susceptible). In conclusion, daptomycin has remained very active against indicated species worldwide, and no significant year-to-year or regional variation in daptomycin activity has been detected.
Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Bacteraemia; Gram-positive infections; Hospital-acquired infections

Mesh:

Substances:

Year:  2014        PMID: 24636430     DOI: 10.1016/j.ijantimicag.2014.01.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  32 in total

Review 1.  Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin.

Authors:  Rose M Kohinke; Amy L Pakyz
Journal:  Curr Infect Dis Rep       Date:  2017-10       Impact factor: 3.725

Review 2.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

Review 3.  Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.

Authors:  Jose M Munita; Barbara E Murray; Cesar A Arias
Journal:  Int J Antimicrob Agents       Date:  2014-09-02       Impact factor: 5.283

4.  β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 5.  Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.

Authors:  Kyle C Molina; Vanthida Huang
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

6.  In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Authors:  Janet A Hindler; Annie Wong-Beringer; Carmen L Charlton; Shelley A Miller; Theodoros Kelesidis; Marissa Carvalho; George Sakoulas; Poochit Nonejuie; Joseph Pogliano; Victor Nizet; Romney Humphries
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

Review 7.  Antimicrobial resistance in nephrology.

Authors:  Tina Z Wang; Rosy Priya L Kodiyanplakkal; David P Calfee
Journal:  Nat Rev Nephrol       Date:  2019-08       Impact factor: 28.314

8.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

9.  Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.

Authors:  Jordan R Smith; Anu Arya; Juwon Yim; Katie E Barber; Jessica Hallesy; Nivedita B Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Deletion of liaR Reverses Daptomycin Resistance in Enterococcus faecium Independent of the Genetic Background.

Authors:  Diana Panesso; Jinnethe Reyes; Elizabeth P Gaston; Morgan Deal; Alejandra Londoño; Masayuki Nigo; Jose M Munita; William R Miller; Yousif Shamoo; Truc T Tran; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.